News and views from the Etcembly team

Etcembly is officially ISO 27001, ISO 42001 and GDPR compliant!

How powerful AI platforms are enabling a new generation of therapeutic bi- and tri-specifics. This year, 2026, marks 40 years since the first monoclonal antibody approval and since then the field of immunotherapy has gone from strength to strength. In the 12 years since the first bispecific approval, multi-specific biologics have already changed how the industry thinks about drug design. Here we’ll explore the potential of trispecifics, identify the pros and cons versus bisp

A promising new drug candidate may have the right target, binding profile, and functional activity, yet still become difficult to progress because its coding sequence does not support efficient protein production. When poor expression is encountered, the usual approach is to redesign the construct, synthesise the new sequence, test again, and repeat.

Therapeutic candidates can only advance as far as their engineering allows. For every molecule that reaches the clinic, hundreds of others are synthesised, tested, and discarded. The problem is rarely that the target was wrong, but rather that the tools used to optimise antibody and TCR affinity, specificity, functional potency, and developability required for a clinical candidate are inefficient. Conventional biologics engineering approaches - whether for antibodies or T cel

In this blog post, we share the story of how AI-guided TCR engineering worked in practice, enabling the optimization of a TCR therapeutic in just weeks, rather than months.

From Months to Minutes: Rewiring Drug Engineering with Al. EMLy Co-pilot Webinar: 12th May 2026 – 9am BST & 4pm BST

This joint study brought together Etcembly’s AI‑designed multi‑specific T cell engagers and Avigen’s cutting‑edge microfluidic avidity platform. It's success marks another step forward in validating AI‑engineered biologics under dynamic, live‑cell conditions.

Building on the success of our previous work together on the MAGE‑A4 TCR — which now underpins ZI‑MA4‑1 and has recently received MHRA approval to enter the clinic — this new partnering between Etcembly and Zelluna focuses on engineering next‑generation KKLC1‑targeting TCRs using our AI‑driven EMLy™ platform.

In this powerful episode of The Futurist, host Ian Khan talks with Michelle Teng on how cancer research is being redefined with the use of artificial intelligence.

See how EMLy Co-Pilot is making biologics discovery faster, smarter and open to all. Read more in Endpoints News.

Imagine discovering new biologics not in weeks, but in minutes...

British techbio innovator Etcembly is recruiting people aged over 18 in the Oxfordshire area who are either healthy, are living with or have survived cancer to participate in their groundbreaking ETCh study aiming to uncover clues to new cancer treatments in their immune cells.

British techbio innovator Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antibody therapeutics.

We're delighted to announce a new partnership with leading antibody manufacturer Vector Laboratories, Inc

Docking Run Interpretation and Annotation Tool (DoRIAT) emerges as a standout innovation

We are delighted that our generative AI platform EMLy™️ has been shortlisted as a finalist in the Fierce Innovation Awards 2024

British techbio innovator Etcembly is teaming up with researchers and clinicians from the University of Surrey to launch a groundbreaking...

British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies

Read the full story about top techbio companies here:

Etcembly launching groundbreaking study to uncover whether cancer survivors hold the key to new cures